SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Myriad Genetics, Inc. (MYGN)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
2355 65 0 MYGN
Emcee:  s myers Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
455<pre>Month Short Interest Percent Change Average Daily Share Volume Daysscaram(o)uche-10/26/2004
454<i>proven ability to get actionable results from complex data...</i>nigel bates-10/26/2004
453I'm not biased...... :-) Cool! Can't see enough of this stuff. Therescaram(o)uche-10/26/2004
452Myriad Genetics, Inc. Enhances Drug Discovery and Development Capability Tuesdaymopgcw-10/26/2004
451Beat me, whip me, make me own an AMGN proxy. Damn, this is boring. First time scaram(o)uche-10/21/2004
450insight in the news, hope they hire lotsa good listeners, constructive sorts, rescaram(o)uche-10/20/2004
449FWIW, NiCox collaborator Basil Rigas has ten abstracts in there concerning precltuck-10/20/2004
448Fun. Thanks! (eom)scaram(o)uche-10/20/2004
447[R-flurbiprofen and anti-PSCA MABs for prostate cancer] Go here: aacr.org Andtuck-10/20/2004
446nothing new, but Nicox is at least aware......... J Neurochem. 2004 Nov;91(3):5scaram(o)uche-10/17/2004
445I can't find any SC-13G for TimesSquare, period. Certainly can't find ascaram(o)uche-10/15/2004
444new....... SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT scaram(o)uche-10/15/2004
443Neuropsychopharmacology. 2004 Oct 06 [Epub ahead of print] Chronic Stress Decrscaram(o)uche-10/8/2004
442There's the Golde et al. tangent on the flurbie story, and there's the Nscaram(o)uche-10/6/2004
441Since HCT-1026 is a COX inhibitor, its side effects in humans are still an issuetuck-10/6/2004
440Int J Immunopathol Pharmacol. 2004 Sep;17(3):317-330. Comparison between flurbscaram(o)uche-10/6/2004
439the only abstract that I can find relating to the "erastin" program atscaram(o)uche-10/3/2004
438Meldrum gave a really solid presentation at UBS. Better definition of IND hopesscaram(o)uche-9/30/2004
437just parking stuff, perhaps useful background for PRLX2113, perhaps garbage.....scaram(o)uche-9/28/2004
436I've been trying to follow NAG-1, for fairly obvious reason. I look, on occscaram(o)uche-9/22/2004
435Meldrum talking at UBS Global Life Sciences, Thursday 9/30, noon....... ibb.ubsscaram(o)uche-9/22/2004
434biotech should look like a sweet spot to most investment professionals. the secscaram(o)uche-9/21/2004
433Rick--The primary reason I'm getting out (75% of my portfolio of biotechs- aJOEBT1-9/21/2004
432Joe: I don't really mind manipulation of biotechs. Biotechs go where scienscaram(o)uche-9/21/2004
431Rick-- I certainly can commiserate with you on what seems like manipulation to cJOEBT1-9/21/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News